Key Points：
- A screenshot circulating on X suggests that Glas may have received FDA marketing authorization for one e-cigarette device and five pods, though no official announcement has been made.
- 2Firsts identified a December 2025–dated e-cigarette authorization list on the FDA website, but the products are not yet listed in the FDA’s searchable database and some links remain inaccessible.
- If confirmed, this would be the first new FDA e-cigarette authorization since Juul in July 2025, potentially signaling a faster pace in PMTA decision-making.
2Firsts, December 21, 2025, Shenzhen-2Firsts observed in the early hours of December 21, 2025 (Beijing time) that X user Gregory Conley posted a screenshot indicating that one device and five e-cigarette pods produced by e-cigarette brand Glas had received Marketing Granted Orders (MGOs) from the U.S. Food and Drug Administration (FDA).
In subsequent verification efforts, 2Firsts identified a file on the FDA website labeled as an “e-cigarette authorization list” updated in December 2025, the contents of which appear highly consistent with the screenshot shared on X. However, the Glas products referenced have not yet appeared in the FDA’s official Searchable Tobacco Products Database, and some related file links are currently inaccessible, leaving the authorization status unconfirmed by formal FDA announcement.
If officially confirmed, this would mark the first new FDA e-cigarette authorization since Juul products received MGOs in July 2025, and may coincide with signs of shifting momentum in the FDA’s PMTA review process.
FDA Database Does Not Yet List Glas Products
Following the disclosure on X, 2Firsts promptly checked the FDA’s Searchable Tobacco Products Database. As of publication, no e-cigarette products associated with Glas are listed in the database.
The database continues to show 39 authorized e-cigarette products in total, with the most recent confirmed authorization granted to Juul in July 2025.
FDA File Status Appears Irregular; “December Update” List Not Formally Published
According to the FDA document link provided by the X user (https://www.fda.gov/media/190229/download), 2Firsts found that the page is no longer accessible and returns a “Page Not Found” error, preventing direct verification of the file via that link.
In further searches, 2Firsts used Google to search for ““Glas Inc.” CTP-250” and found search results indicating that a PDF file hosted on the FDA website contains references to products including “Glas Inc. BLONDE TOBACCO 50 MG/ML Pod,” “CLASSIC MENTHOL 50 MG/ML Pod,” and “FRESH,” though the file itself could not be opened.
By following the FDA’s typical public document numbering patterns, 2Firsts identified a neighboring link (https://www.fda.gov/media/190230/download), which leads to a low-resolution image file titled “Authorized-E-Cigarettes-List.jpg.” While the image is blurred and lacks full clarity, its layout and visible entries appear consistent with the screenshot circulated on X, and the list includes “Glas Inc.” and associated products.
Possible Indication FDA Review Is Complete, Pending Formal Announcement
Based on these observations, one possible explanation is that the FDA has completed its internal review and authorization process for Glas-related e-cigarette products and uploaded an updated authorization list internally, but that the document has not yet entered the formal public release process or was temporarily removed during publication. Technical or caching factors may have resulted in a residual image version remaining accessible on the server.
As of now, the FDA has not issued any public statement regarding the status of the file or the authorization of Glas products.
If Confirmed, Authorization May Signal Regulatory Shift on Flavor and Age Verification
According to the circulating authorization list screenshot, Glas’s approved products appear to include at least one flavor that, based on its name, does not fall under traditional tobacco or menthol categories.
Previous media reports have indicated that Glas’s PMTA strategy centered on its proprietary age-restriction or age-verification platform, designed to address FDA concerns regarding youth access. If the authorization is ultimately confirmed, this could represent the first FDA-approved e-cigarette products combining age-verification technology with non-traditional flavors—an outcome that could be viewed as a significant regulatory development in the U.S. e-cigarette market.
Signs of Accelerating PMTA Review Pace
On December 19, 2025 (U.S. Eastern Time), the FDA announced that it had granted marketing authorization to certain on! PLUS nicotine pouch products under Altria.
If Glas’s e-cigarette authorization is confirmed, it would further reinforce market perceptions that the FDA is accelerating PMTA decision-making across both e-cigarette and nicotine pouch categories.
2Firsts has submitted an interview request to the FDA regarding the authorization status of Glas’s e-cigarette products and the apparent publication and removal of related documents. No response had been received as of publication.
2Firsts will continue to monitor and report on developments in U.S. PMTA reviews and regulatory policy.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
